01—Abstract
Summary
Summary of the 8-K filed November 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc. reported its financial results for the third quarter of 2026, announcing a significant increase in revenue from its launched and acquired products, which grew by 32%a operationally.
This strong performance, combined with disciplined operational execution, has led the company to raise its full-year 2026 guidance for both revenue and adjusted diluted earnings per share (EPS). The company's non-COVID products showed robust operational revenue growth of 7%b. Key advancements in its late-stage pipeline across oncology, immunology, and vaccines were also highlighted, with multiple upcoming catalysts expected to drive future value.
Pfizer has also announced the appointment of Cecile Guegan as its new Chief Financial Officer and Executive Vice President. Despite an overall flat year-over-year revenue for the quarter, the underlying growth drivers from its diversified portfolio and promising pipeline position Pfizer for continued long-term shareholder value creation.
02—Key points
Key Highlights
- Pfizer reported 32% operational revenue growth from launched and acquired products in Q3 2026.
- The company raised its full-year 2026 revenue guidance to a range of $62.0 to $64.0 billion.
- Full-year 2026 adjusted diluted EPS guidance was raised and narrowed to $2.95 to $3.05.
- Non-COVID product revenues grew by 7% operationally in the third quarter.
- The company highlighted significant progress in its late-stage pipeline with multiple key catalysts ahead.
- Cecile Guegan has been appointed as the new Chief Financial Officer and Executive Vice President.
- Revenue from Eliquis, Padcev, and the Vyndaqel family showed strong operational growth.
03—Questions
Frequently Asked Questions
What is the overall financial performance for Pfizer in the third quarter of 2026?
Pfizer reported total revenues of $16.6 billion for the third quarter of 2026, which was relatively flat year-over-year on an operational basis. However, excluding contributions from Comirnaty and Paxlovid, revenues grew by 7% operationally. Notably, revenues from launched and acquired products saw a substantial 32% operational increase.
Why has Pfizer raised its full-year 2026 financial guidance?
The company raised its full-year 2026 guidance due to strong year-to-date performance and confidence in its business outlook. Specifically, revenue guidance was increased by $1.5 billion at the midpoint, and adjusted diluted EPS guidance was raised and narrowed, reflecting the positive momentum.
What are the key drivers of revenue growth mentioned in the report?
The key drivers of operational revenue growth include significant increases from Eliquis (25%), Padcev (55%), the Vyndaqel family (12%), Nurtec ODT/Vydura (33%), and Lorbrena (43%). These products are contributing to the overall growth, offsetting declines in COVID-19 products and other legacy products.
What is the company's capital allocation strategy?
Pfizer's capital allocation strategy focuses on reinvesting in the business through R&D and business development, maintaining and growing its dividend, and potentially resuming share repurchases after de-levering its balance sheet. In the first nine months of 2026, $8.3 billion was invested in R&D and approximately $850 million in business development, with $7.3 billion returned to shareholders via dividends.
04—Continue